Comment
. 2010 Dec 7;122(23):e576; author reply e577.
doi: 10.1161/CIRCULATIONAHA.110.954016.
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials"
- PMID: 21135369
- DOI: 10.1161/CIRCULATIONAHA.110.954016
Item in Clipboard
Comment
Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials"
Circulation.
.
No abstract available
Comment on
-
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22. Circulation. 2010. PMID: 20176986 Free PMC article. Clinical Trial.
Similar articles
-
Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".Circulation. 2010 Dec 7;122(23):e575; author reply e577. doi: 10.1161/CIRCULATIONAHA.110.953216. Circulation. 2010. PMID: 21135368 No abstract available.
-
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.
-
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031900 Clinical Trial.
-
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.J Am Coll Cardiol. 2009 Mar 17;53(11):931-5. doi: 10.1016/j.jacc.2008.12.010. J Am Coll Cardiol. 2009. PMID: 19281922 Clinical Trial.
-
The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Postgrad Med. 2009. PMID: 19491548 Review.
Cited by
-
Considerable uncertainty remains in the evidence for primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2011 Jan 14;2011(8):ED000017. doi: 10.1002/14651858.ED000017. Cochrane Database Syst Rev. 2011. PMID: 21833976 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
